Lilium Otsuka becomes part of Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; “OPF”) has signed a Share Purchase Agreement to acquire all the shares of Lilium Otsuka Co., Ltd. (Head Office: Sagamihara, Kanagawa, Japan; President and Representative Director: Isao Shirasaki; “Lilium Otsuka”) held by Otsuka Medical Devices Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President and Representative Director: Noriko Tojo; “Otsuka Medical Devices”). The acquisition of the shares has been completed today and Lilium Otsuka becomes a wholly owned subsidiary of OPF.

Lilium Otsuka has engaged in the business as one of the wholly owned subsidiaries of Otsuka Medical Devices which oversees medical device operations of the Otsuka group. In April 2016, OPF and Lilium Otsuka signed an exclusive sales agreement for the portable ultrasonic diagnostic device “Lilium® α-200” (“Lilium α-200”). OPF has been expanding sales of the product by utilizing its wide range of network through clinical nutrition products in settings from acute care hospitals to homes. By making Lilium Otsuka a wholly owned subsidiary of OPF and integrating manufacturing and distribution, OPF will further strengthen the business structure and strategically develop products related to nephrology, renal surgery, and urology of the Otsuka group. We can establish a system which can smoothly meet requests from patients and healthcare professionals by this agreement.

Otsuka group will continue to contribute to the health of people around the world based on its corporate philosophy of Otsuka-people creating new products for better health worldwide.